Loading company…
Seoul-based pharmaceutical R&D company developing PROTAC technology to treat cancer and intractable diseases.
Founded in 2018 and based in Seoul, South Korea, Ubix Therapeutics researches and develops new drugs using Proteolysis Targeting Chimera (PROTAC) technology, an inhibitor cell technology aimed at cancer and intractable diseases. In March 2023 it raised KRW 12 billion in Series C funding from new investors Scale Up Partners, QUAD Ventures, Medytox Venture Investment, GeneN Investment Partners and BNH Investment. Returning investors UTC Investment, Mirae Asset Venture Investment and Atinum Investment also took part. CEO is Bo-Kwang Seo.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in